Astegolimab for Long-Term COPD Safety

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Recruiting Phase 3 Interventional Study
Chronic Obstructive Pulmonary Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 90
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
2,000 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for people with chronic obstructive pulmonary disease (COPD) who have completed a 52-week treatment period in a related study. Participants will help researchers understand the long-term safety and effectiveness of astegolimab.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have completed a 52-week treatment period in a related study.

You may not be able to join if

  • I withdrew my consent from the previous study.
  • I discontinued the study drug permanently in the previous study.
  • I missed scheduled visits during the previous study.
  • I was diagnosed with asthma since enrolling in the previous study.
  • I have a new clinically significant lung disease other than COPD.
  • I have new unstable heart disease or heart failure since enrolling in the previous study.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Completion of the 52-week treatment period in an astegolimab parent study Exclusion Criteria: * Withdrawal of consent and/or premature discontinuation from parent study * Any permanent discontinuation of study drug in parent study * Significant non-compliance in the parent s…
Contacts

Reference Study ID Number: GB43374 https://forpatients.roche.com/ No attachments to email below.

888-662-6728

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT